KEYTRUDA 25 mg/mL concentrate for solution for infusion, Datopotamab deruxtecan, KEYTRUDA 25 mg/mL concentrate for solution for infusion
DS1062-A-U304
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, Datopotamab deruxtecan, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) is a Phase 3 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Daiichi Sankyo Europe GmbH
- Indication
- Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active